Only bad things, not the normal cells. But if immune cells are excessively working, then uh, that's called abnormal immune cell also attacks normal cells that is, uh, like autoimmune diseases or in the lower level is the allergy. Right. So this was evaluated in different types of autoimmune diseases like this. These are the, uh, different types of autoimmune diseases. AHCC had ever evaluated, right? Then AHCC is basically for such excessive, uh, over expressing immunity. AHCC is supposed to, uh, suppress and get back to the normal proper working level of immunity. So this from next, in a siloed function. So I'm going to show two studies. A on siloed function, autoimmune disease, Grave's disease, and Hashimoto disease. Right? So Grave's disease is, uh, over expressing thyroid function. Right. And AHCC was effective, it was shown by clinical cases and small disease is a low profile of thyroid function and AHCC was also effective, improved the symptoms.
So this is really good examples showing the thyroid function in over expressing or lower expressing and AHCC was effective in both cases. Yeah. So this is really kind of, um, good idea. It is, uh, I, you, you probably get a good idea. AHCC can work in both ways. But anyway, that is a basic a idea. We, we also have for AHCC for autoimmune diseases, but at the same time autoimmune diseases are very complicated caused by really person by person. Really case by case. Totally different. So it is really a very difficult to generalize or conclusive about the effect of AHCC. So we always recommend and suggest doctors and patients to start from very low dosage. Yeah. Then should be very watchful about the symptoms. If any case worsens, any symptoms are worsening, then they should immediate immediately stop AHCC. But in most cases we, we think, uh, we believe AHCC shows improve the symptoms through so that uh, they can increase a, gradually increase the dosage of a AHCC and come to the probably normal therapeutic dosage. So in the beginning, very beginning should start from the lower dosage. Yeah. And should be very watchful about the symptoms.
Okay. So, um, this is the last study A from University of Ottawa. You have seen professor Chantel Matar. She has been evaluating AHCC on cancer stem cell. And she is going to, uh, speak first today. So I'm going to, not to to talk too much, but basically cancer stem cell. It is very important to understand what the cancer stem cell is. Cancer stem cell is like a stem cell, but it turn to be cancer. It will turn to be cancer. So cancer stem cell is not cancerous yet, but it's going to be cancer eventually. That is a cancer stem cell. And with such a chemotherapy radiotherapy treatment, cancer stem cell is not the target of the drug. So it will survive in the body and they keep hiding in, in the body for while. Then cancer stem cell can be proliferated to be cancerous.
Then such a recurrence happens. That is a cancer stem cell. Also, it is said, uh, cancer stem cell is also involved in every initiation of cancer in the very beginning. So controlling cancer stem cell is very, very important. And that is a topic of Chantel's. So, um, simply saying a, her study is evaluating AHCC effect on certain, uh, epigenetics control to express the level of micro RNA that is involved relevant to the expressing the, specific type of protein that to work the proliferation of cancer stem cell. So from her study is AHCC worked on those different types of cancer stem cells in vitro and in vivo, and she is evaluating certain level, certain, microRNA expression level and it's working, making the double expression and if they induces the changes in level of the tenancy. So micro, this is a study she has shown that this certain microRNA AHCC changes is a controlling, this 10 C protein excretion.
And that is a then in, it was shown in the mice model that AHCC influences and changes that level of cancer stem cell proliferation. So it was all related. And she is also evaluating that epigenetics control from the, um, prebiotics a function as a one function of AHCC. So she is going to talk about a breast gut axis. Yeah, that's a really new term. She created, I believe it's a really, uh, there, she's trying to say there's a really certain connection from gut microbiome to breast as a hard study, and I'd like to note that, uh, harsh Chantel study a research is the collaboration with cancer center of WHO. Yeah. So this, in her slide you will see WHO name on her a title slide. Now this is really the first, uh, research, uh, first AHCC research that WHO researchers are involved.
So we are very excited and she's now working on a, uh, three or four manuscript out of her study. So we are expecting that to be published very soon. Yeah. One, one manuscript is on my hand right now. I need to review it. So I've actually stopped the process, but that, that's just because of this complex. So that was a summary of AHCC, um, mechanism is validated and we have a great health support benefit, health maintenance prevention and clearance and virus infectious diseases and using oncology. And this is a Chantel's new mechanism, nutrigenomics nutrition working on genomics. That was about this. Go ahead. Yes. One comment one minute please. Okay.
So just on the commercial side, um, obviously there's just a wealth of research here. So one of our challenges on the business side is how we can utilize the wealth of research and communicate that out to the patients. And so one of the challenges in, in the US Canadian market, which I'm sure you experience a lot, is regulatory. So what we do is for every basically point that we want to communicate, we generally find a writer and have them write an independent article answering the question. So for example, drug to drug interaction, we have a study on that. We have an article on that autoimmune disease. We have an article on that. Uh, what happens if you discontinue taking AHCC? We have an article on that confusion between AHCC and Active hexo. So we have that whole library we can distribute to you guys, and then you can circulate it as independent third party research.
And in many countries like the US you're allowed to do that as long as you don't mix it with a commercial product. We also have a book in the US on AHCC, which has been translated and then Amino produced the book for doctors. So there's a lot of collateral. So I would encourage you to ask us and then we'll provide it to you guys and you can use that to educate the market. So I just wanted to mention that. Thank you.
So all those, uh, recent clinical researchers are now available as a book, the Clinicians Guide to AHCC. And this is, uh, available only for the printing cost. We are not making any money by sending this book, but just by printing costs, this book is available. So if you're interested, appreciate us. All right. Uh, do you need a break or yeah, need a break? Five minutes. Five minutes break. Yes, please. Well, please go ahead for the break.